|
|
Effect of Anticoagulation Intervention on Inflammatory Factors in Rats with Chronic Obstructive Pulmonary Disease and Its Correlation with Thrombosis Factor |
CAO Xiao-ming, MA Zhi-yi, LIANG Rong-zhang, LIU Xiao-hong |
Longyan First Affiliated Hospital of Fujian Medical University, Fujian Longyan 364000, China |
|
|
Abstract Objective: The goal of this study was to investigate the effect of anticoagulant intervention on inflammatory factors in rats with chronic obstructive pulmonary disease(COPD) and its correlation with thrombus factors. Methods: Sixty Wistar rats were randomly assigned to one of three groups: model group(n=20), anticoagulation intervention group(n=20), and healthy control group. The rats in the healthy control group were fed normally, with no special treatment. The rats in the model group and the anticoagulation intervention groups had COPD models created by cigarette smoking combined with intratracheal injection of lipopolysaccharide. Following successful modeling, rats in the model group received a subcutaneous injection of normal saline, while the rats in the anticoagulation intervention group received a subcutaneous injection of low molecular weight heparin sodium. The three groups were compared in terms of lung histomorphology, pulmonary function measures, serum levels of inflammatory and thrombotic markers. The link between inflammatory variables and thrombus components in COPD model rats was determined using Pearson correlation analysis. Results: The mean lining interval (MLI) and the ratio of alveolar area to total lung area(PAA) in the model group and the anticoagulation groups were larger than those in the healthy control group, whereas the mean alveolar number(MAN) was lower. MLI and PAA were lower in the anticoagulation intervention group than in the model group, whereas MAN was higher in the model group(P<0.05). Tidal volume, minute ventilation, and FEV1/FVC were lower in the model and anticoagulation intervention groups than in the healthy control group, but lung compliance was higher in the model and anticoagulation intervention groups. Tidal volume, minute ventilation volume, and FEV1/FVC were higher in the anticoagulation intervention group than in the model group, whereas lung compliance was worse in the model group(P<0.05). The serum levels of tumor necrosis factor-α(TNF-α), interleukin-8(IL-8) and interleukin-6(IL-6) in the model and anti-coagulation intervention groups were higher than those in the healthy control group, but lower in the anti-coagulation intervention group than in the model group(P<0.05). The serum levels of tissue factor(TF) and tissue factor pathway inhibitor-1(TFPI-1) were higher in the model group and anticoagulation intervention groups than those in the healthy control group, while the levels of the above thrombotic factors were lower in the anticoagulation intervention group than those in the model group(P<0.05). Pearson correlation analysis revealed that TNF-α, IL-8 and IL-6 levels were favorably linked with TF and TFPI-1 levels in COPD model rats(P<0.05). Conclusion: Anticoagulant therapy can successfully enhance pulmonary function in COPD rats, while also negatively regulating inflammatory and thrombus factors, and there is a strong link between inflammatory factors and thrombus factors.
|
Received: 15 March 2023
|
|
Corresponding Authors:
LIU Xiao-hong. E-mail: caoxiaoming8729@163.com
|
|
|
|
[1] Jiménez D, Agustí A, Tabernero E,et al.Effect of a pulmonary embolism diagnostic strategy on clinical outcomes in patients hospitalized for COPD exacerbation: A randomized clinical trial[J].JAMA,2021,326(13):1277-1285. [2] Liu X, Jiao X, Gong X, et al.Prevalence, risk factor and clinical characteristics of venous thrombus embolism in patients with acute exacerbation of COPD: A prospective multicenter study[J]. Int J Chron Obstruct Pulmon Dis,2023,18(18):907-917. [3] Castellana G, Intiglietta P, Dragonieri S,et al.Incidence of deep venous thrombosis in patients with both pulmonary embolism and COPD[J]. Acta Biomed,2021,92(3):e2021210. [4] Yang M, Xu Y, Chen H, et al.Benefits and risks of low molecular weight heparin in patients with acute exacerbation of chronic obstructive pulmonary disease: a meta-analysis of randomized controlled trials[J]. Inflammopharmacology,2020,28(2):451-462. [5] Zhao D, Feng JF.Efficacy of low molecular weight heparin for chronic obstructive pulmonary disease and respiratory failure: A protocol of systematic review of randomized controlled trials[J]. Medicine (Baltimore),2019,98(48):e18051. [6] Lu Z, Van Eeckhoutte HP, Liu G, et al.Necroptosis signaling promotes inflammation, airway remodeling, and emphysema in chronic obstructive pulmonary disease[J]. Am J Respir Crit Care Med,2021,204(6):667-681. [7] Wronski S, Beinke S, Obernolte H, et al.Rhinovirus-induced human lung tissue responses mimic chronic obstructive pulmonary disease and asthma gene signatures[J]. Am J Respir Cell Mol Biol,2021,65(5):544-554. [8] Cheng Y, Liu B, Qian H,et al.BAY11-7082 inhibits the expression of tissue factor and plasminogen activator inhibitor-1 in type-II alveolar epithelial cells following TNF-α stimulation via the NF-κB pathway[J]. Exp Ther Med,2021,21(2):177. [9] Shute JK.Heparin, low molecular weight heparin, and non-anticoagulant derivatives for the treatment of inflammatory lung disease[J].Pharmaceuticals (Basel),2023,16(4):584. [10] Wang T, Chen X, Li H, et al.Pro-thrombotic changes associated with exposure to ambient ultrafine particles in patients with chronic obstructive pulmonary disease: roles of lipid peroxidation and systemic inflammation[J].Part Fibre Toxicol,2022,19(1):65. |
[1] |
CHEN Wan-ling, ZHANG Cheng-yuan, LIU Hai-hua. Effects of Recombinant Human Growth Hormone on Corneal Healing, Epithelial Nerve Regeneration and Tear Inflammatory Factors in Rabbits[J]. Chinese Journal of Biomedical Engineering, 2023, 32(2): 55-64. |
[2] |
GUO Chun-hua, LI Hua-qing, LIN Zheng, QIU Zhao-wen, DENG Jin-xiu, ZHANG Qiu-xia, LIN Yong. Correlation between the Expression of TGF-β1, Rhoa, SOX9 and Renal Interstitial Fibrosis in Rats with Chronic Kidney Disease[J]. Chinese Journal of Biomedical Engineering, 2023, 32(2): 65-72. |
|
|
|
|